News | May 21, 2025
Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
CRL shall invest another Rs. 200 crore for creation of additional beds
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
The CDMO upgrade represents a transformational step for Remedium Lifecare
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Scores highest PAT of Rs. 118 crore in FY25
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Subscribe To Our Newsletter & Stay Updated
